BioSpace News Archive

The California biotech aspires to be a catalyst for the acceleration of gene therapy across a range of therapeutic areas, beginning with three serious neurodegenerative disease targets.

Levitt has practiced law for over 20 years in the FDA regulatory space. Previously chief regulatory counsel for Pfizer Inc., Levitt has had extensive experience working with an interdisciplinary team of scientists, executives and lawyers to push a candidate to market.

Pfizer is expanding its presence in infectious diseases with the acquisition of San Diego-based Amplyx Pharmaceuticals and its lead antifungal compound Fosmanogepix.

Alpha-9 Theranostics announced the closing of an $11 million Series A financing today, while Engage Technologies also announced it has raised money in a Series A round, funding that came in at a tune of $15 million.

Texas is quickly becoming a hotbed of biopharmaceutical activities, with Houston being one of the two top cities in the state that is leading the way.

Biopharma and life sciences companies from across the globe provide updates on their businesses and pipelines.

ICON plc, a global provider of outsourced drug and device development and commercialisation services to pharmaceutical, biotechnology, medical device and government and public health organisations, reported its financial results for the first quarter ended March 31, 2021.

Advaxis, Inc. (Nasdaq: ADXS), a clinical-stage biotechnology company focused on the development and commercialization of immunotherapy products, today announced that will present data from Part B of the Phase 1 study of ADXS-503 in combination with pembrolizumab at the American Society of Clinical Oncology (ASCO) Annual Meeting being held virtually, on June 4-8, 2021

Checkmate Pharmaceuticals Inc. (NASDAQ: CMPI) (“Checkmate”), a clinical stage biopharmaceutical company focused on developing its proprietary technology to harness the power of the immune system to combat cancer, today announced that Barry Labinger, CEO, will present at the upcoming Bank of America Securities 2021 Virtual Healthcare Conference at 1:15pm ET on Wednesday, May 12, 2021

Stealth BioTherapeutics Corp (Nasdaq: MITO), a clinical-stage biotechnology company focused on the discovery, development, and commercialization of novel therapies for diseases involving mitochondrial dysfunction, today announced that the company will have a poster presentation with a live discussion at the upcoming 2021 Association for Research in Vision and Ophthalmology (ARVO) Virtual Annual Meeting